Table 2.
Overall survival stratified by clinical features and univariate Cox proportional hazard analyses for PCCCL patients.
| Variables | Mean survival months | 95% CI | Univariate analysis | |
|---|---|---|---|---|
| HR [95%CI] | P-value | |||
| Total | 25.6 | 22.2–29 | ||
| Age (years) | ||||
| ≤60 | 27.7 | 21.6–33.8 | Ref | |
| 61–70 | 30.5 | 23.6–37.5 | 0.93 (0.68–1.27) | 0.665 |
| >70 | 18.8 | 14.5–23.2 | 1.22 (0.9–1.64) | 0.200 |
| Gender | ||||
| Female | 33.1 | 22.5–33.1 | Ref | |
| Male | 36.6 | 20–28.8 | 1.04 (0.8–1.34) | 0.793 |
| Race | ||||
| White | 25.6 | 21.4–29.9 | Ref | |
| Black | 21.3 | 12.1–30.6 | 1.14 (0.77–1.69) | 0.517 |
| Marital status | ||||
| Married | 27.1 | 23.1–31.1 | Ref | |
| Single | 19.6 | 13.4–25.8 | 1.33 (0.97–1.83) | 0.079 |
| Grade | ||||
| Well | 31.6 | 22.3–40.8 | Ref | |
| Moderately | 31.3 | 24.8–37.8 | 0.82 (0.55–1.24) | 0.358 |
| Poor and undifferentiated | 34.5 | 20.5–48.5 | 0.96 (0.58–1.59) | 0.872 |
| Tumor stage | ||||
| T1 | 36.9 | 30.5–43.3 | Ref | |
| T2 | 32.8 | 22.3–43.3 | 1.08 (0.7–1.68) | 0.723 |
| T3 | 12.6 | 8.7–16.5 | 3.2 (2.25–4.56) | <0.001 |
| T4 | 14.1 | 9.4–18.8 | 3.01 (2.16–4.19) | <0.001 |
| Tumor size | ||||
| ≤37 mm | 49.2 | 39.7–58.7 | Ref | |
| 37–96 mm | 28.7 | 23.1–34.4 | 2.7 (1.79–4.12) | <0.001 |
| >96 mm | 15.1 | 10.1–20.1 | 5.28 (3.37–8.28) | <0.001 |
| Lymph node metastases | ||||
| N0 | 28.4 | 24.4–32.4 | Ref | |
| N1 | 8.1 | 3.8–12.3 | 2.63 (1.51–4.58) | <0.001 |
| Distant metastases | ||||
| M0 | 30.4 | 26.2–34.6 | Ref | |
| M1 | 7.7 | 5.1–10.3 | 3.25 (2.38–4.45) | <0.001 |
| Summary stage | ||||
| Localized | 35.7 | 30.5–41 | Ref | |
| Regional | 18.3 | 12.4–24.2 | 2.11 (1.55–2.88) | <0.001 |
| Distance | 7.7 | 5.1–10.3 | 4.17 (2.98–5.84) | <0.001 |
| TNM stage | ||||
| I | 39.9 | 32.9–46.9 | Ref | |
| II | 35.7 | 23.7–47.7 | 1.04 (0.62–1.73) | 0.882 |
| III | 17.4 | 12.3–22.5 | 3.03 (2.11–4.36) | <0.001 |
| IV | 7.7 | 5.1–10.3 | 5.73 (3.88–8.46) | <0.001 |
| AFP level | ||||
| Elevated | 22.3 | 17.8–26.7 | Ref | |
| Normal | 31.9 | 23.9–39.9 | 0.51 (0.34–0.78) | <0.001 |
| Fibrosis score | ||||
| 0–4 | 28.2 | 20.3–36.2 | ||
| 5–6 | 33.6 | 21.7–45.4 | 1.09 (0.61–1.95) | 0.790 |
| Surgery type | ||||
| Local ablation | 33 | 22.8–43.3 | Ref | |
| Resection | 45.2 | 37.4–53.1 | 0.99 (05–1.97) | 0.980 |
| Transplant | 100.2 | 65.0–135.4 | 0.1 (0.01–0.77) | 0.02 |
| Surgery | ||||
| No | 12.7 | 10.3–15 | Ref | |
| Yes | 47.3 | 40.3–54.4 | 0.23 (0.17–0.31) | <0.001 |
| Radiation | ||||
| No | 26.3 | 22.7–29.9 | Ref | |
| Yes | 15.7 | 9.2–22.3 | 1.4 (0.87–2.27) | 0.169 |
| Chemotherapy | ||||
| No | 26.1 | 21.7–30.4 | Ref | |
| Yes | 24.6 | 19.3–29.8 | 1.11 (0.85–1.45) | 0.441 |
PCCCL – primary clear cell carcinoma of the liver; AFP – alpha-fetoprotein; CI – confidence interval; HR – hazard ratio.